English

Nuevolution appoints Nomination Committee

Report this content

Stockholm, 30 October 2018 – Nuevolution AB (publ) (NUE.ST) today announced that a Nomination Committee consisting of members appointed by the three largest shareholders and the Chairman of the Board of Directors has been formed for Nuevolution AB in accordance with the principles adopted by the annual general meeting held on 28 May 2018. The Nomination Committee shall, before the Annual General Meeting 2019, prepare proposal for the election of Chairman and other members of the Board of Directors, the election of Chairman of the Annual Meeting, election of Auditors, the determination of fees and matters pertaining thereto.

The members of the Nominations Committee are:

  • Peter Benson, appointed by Sunstone
  • Filip Petersson, appointed by SEB Venture Capital
  • Patrik Sobocki, appointed by Industrifonden
  • Stig Løkke Pedersen, Chairman of the Board in Nuevolution AB

Shareholders wishing to submit a proposal for members of the Board of Directors may do so by sending e-mail to the Chairman of the Board of Directors of Nuevolution AB at: agm@nuevolution.com. Proposals should, in order to be timely assessed by the Nomination Committee, be submitted no later than seven weeks in advance of the meeting.

The Annual General Meeting 2019 in Nuevolution will be held on 22 May 2019 in Stockholm. Shareholders who want to have a matter addressed at the Annual General Meeting 2019 must submit such a proposal to the same address as above (subject “Annual General Meeting 2019” for the e-mail and the letter, respectively) seven weeks in advance of the meeting at the latest.

For more information, please contact:

Alex Gouliaev, CEO

Phone: +45 2725 1402

Email: ahg@nuevolution.com

Johnny Stilou, CFO

Phone: +45 8877 5973

E-mail: jost@nuevolution.com

Information about Nuevolution AB (publ)

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and develops its programs alone and in collaboration with pharmaceutical and biotechnology companies to seek future benefit for patients in need of novel medical treatment options. Nuevolution’s internal programs are focused on therapeutically important diseases targets within severe inflammatory diseases and cancer.

This information was sent for publication, through the agency of the contact persons set out above, on Tuesday 30 October 2018 at 17.30 CET.

Nuevolution AB (publ) is listed at Nasdaq in Stockholm, Sweden (ticker: NUE). More information about Nuevolution can be found on: www.nuevolution.com

Documents & Links